GSK

Monoclonal antibodies
#Colorectal cancer #GSK #Immunotherapy #Monoclonal antibodies #Oncology #US Food and Drug Administration (FDA)

FDA approves first immunotherapy for advanced rectal cancer

The US Food and Drug Administration (FDA) has granted accelerated approval for a new use of the immunotherapy Jemperli (dostarlimab-gxly).  The approval is for Jemperli used alone in adults with previously untreated stage II or stage III locally advanced rectal cancer.  Patients with locally advanced… Read More

#Cancer Research #News #Regulatory #Trending News

Multiple myeloma
#Cancer research #Chimagen Biosciences #GSK #Multiple myeloma #Oncology

GSK to acquire potential asset for multiple myeloma  

GSK has entered an agreement to acquire a potential best-in-class trispecific T cell-engager (TCE) from Chimagen Biosciences, a privately held biotechnology company. GSK plans to develop and commercialise the asset for multiple myeloma, with the programme expected to enter Phase I trials in 2027.  TCEs have shown… Read More

#News

Flu vaccine
#GSK #Immunology / Virology & Vaccines #Influenza #mRNA #mRNA-based vaccines

GSK reveals plans to advance mRNA flu vaccine to Phase III

GSK has revealed that its mRNA seasonal influenza (flu) vaccine candidate has shown higher immune responses against all influenza strains tested compared to licensed standard dose and high dose inactivated flu vaccines.  The Phase II data were presented at the OPTIONS XIII Conference for the Control of… Read More

#News

Human data concept
#AI / data analytics / healthtech / informatics #Collaboration #GSK #Relation

GSK teams up with Relation to improve disease biology knowledge

Pharmaceutical company GSK has announced a strategic collaboration with the biotech Relation to improve the understanding of disease biology and support the discovery of new therapeutic targets.  Specifically, the partnership will focus on generating large-scale human cellular perturbation data and deploying them into models, such as Relation’s… Read More

#Business & Investment #News

GSK offices
#European Medicines Agency #FDA #GSK #Orphan drugs #Rare disease

JAK inhibitor for VEXAS syndrome gets orphan drug designations

GSK’s momelotinib, a JAK inhibitor with a differentiated mechanism of action, has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome.   VEXAS syndrome is a clonal… Read More

#News #Regulatory

GSK offices
#Biopharma #GSK #Non-small cell lung cancer (NSCLC)

GSK acquires Nuvalent and cancer therapy pipeline 

GSK has reached an agreement to acquire biopharmaceutical company Nuvalent for $10.6 billion.  The agreement includes GSK’s purchase of three therapies for lung cancer, including Zidesamtinib (NVL-250) and neladalkib (NVL-655). The candidates are late-stage, potential best-in-class, next-generation, highly selective ROS1 and ALK inhibitors for treatment of non-small cell… Read More

#Business & Investment #News #Trending News

#Clinical trial #GSK #Protas

GSK signs agreement to streamline clinical trials 

GSK has announced an agreement with Protas to streamline clinical trials of vaccines and therapeutics.  The three-year agreement sets out to build on an existing two-year relationship and will broaden the scope of work across numerous projects. This includes Phase II and III trials within GSK’s respiratory,… Read More

#News

Ovarian cancer cells
#GSK #Oncology #Ovarian cancer #Phase I trial

B7-H4-targeted ADC shows 62% response rate in ovarian cancer

The global Phase I BEHOLD-1 clinical trial for mocertatug rezetecan (Mo-Rez) has shown confirmed objective response rates (cORR) of 62% in platinum-resistant ovarian cancer (PROC) and 67% in recurrent or advanced endometrial cancer (EC).  Mocertatug rezetecan is a novel antibody-drug conjugate (ADC) targeting the B7-H4 antigen. B7-H4… Read More

#Cancer Research #Editor's Choice #News

#GSK #Hypertension #Mergers and acquisitions

GSK buys 35Pharma for pulmonary hypertension treatment

GSK will pay $950 million for Canadian biopharmaceutical company 35Pharma, specialised in the development of novel protein-based therapeutics.  The acquisition includes HS235, a potential best-in-class investigational medicine that has completed Phase I healthy volunteer clinical trials, with studies to start imminently in pulmonary arterial hypertension (PAH) and… Read More

#Business & Investment #News

European Commission
#European Commission #GSK #Respiratory syncytial virus #Vaccines

European Commission approves RSV vaccine 

The European Commission (EC) has approved a respiratory syncytial virus (RSV) vaccine for the treatment of adult patients with lower respiratory tract disease (LRTD) caused by RSV.  Arexy, an adjuvanted recombinant RSV vaccine developed by GSK, will now be available to adult patients in European countries. The… Read More

#News #Regulatory

GSK offices
#Allergy #GSK #Mergers and acquisitions #Monoclonal antibodies #RAPT Therapeutics

GSK expands food allergy pipeline with RAPT purchase

GSK has entered a definitive agreement to acquire RAPT Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for inflammatory and immunologic diseases.   The acquisition includes ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody, currently in Phase IIb clinical development for prophylactic protection against food allergens. … Read More

#Business & Investment #News

#Antisense Oligonucleotides (ASOs) #CAMP4 Therapeutics #Collaboration #GSK #Kidney disease #Neurodegenerative disorders

CAMP4 and GSK advance RNA-based therapeutic discoveries

GSK and CAMP4 Therapeutics have entered into a strategic research, collaboration and license agreement to identify and develop antisense oligonucleotide (ASO) drug candidates for multiple gene targets relevant to neurodegenerative and kidney disease indications.  “Protein under-expression plays a critical role in diseases such as neurodegenerative and kidney… Read More

#Business & Investment #News

GSK offices
#CHMP #European Medicines Agency #GSK #Respiratory

CHMP supports two GSK respiratory drugs for 2026 approval

GSK has announced positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending the approval of two new potential medicines for respiratory diseases.  Depemokimab has been recommended as add-on maintenance treatment for severe asthma with type 2 inflammation (12+) and… Read More

#News #Regulatory

#Antimicrobial resistance (AMR) #Bacteria #Cancer research #CAR T-cell therapy #GSK #Gut microbiome #Lung cancer #Oncology #Osteosarcoma #UK government

DDW Highlights: 25 November 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, research into bacterial species and diseases broke new ground. Elsewhere, vaccines could… Read More

#Podcasts